Abstract
BackgroundHepatocellular carcinoma (HCC) is a low TMB tumor with largely immune-excluded phenotype. Anti-PD1 monotherapy for 2L HCC has response rates of 12-18%. Therapeutic cancer vaccines targeting neoantigens can generate tumor-specific...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
